GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Inventories, Finished Goods

GLPG (Galapagos NV) Inventories, Finished Goods : $0.0 Mil (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Inventories, Finished Goods?

Galapagos NV's annual finished goods increased from Dec. 2021 ($5.5 Mil) to Dec. 2022 ($8.5 Mil) but then declined from Dec. 2022 ($8.5 Mil) to Dec. 2023 ($6.7 Mil).

Galapagos NV Inventories, Finished Goods Historical Data

The historical data trend for Galapagos NV's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Inventories, Finished Goods Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.04 5.47 8.54 6.67

Galapagos NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.67 - - -

Galapagos NV Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Galapagos NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Inventories, Finished Goods
Comparable Companies
XAMS:PHARM XAMS:BAI XAMS:VVY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE UTHR MRNA SMMT INCY OCSE:GMAB INSM SHSE:603392
Traded in Other Exchanges
GLPGF:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Website
https://www.glpg.com
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.